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Abstract
Objective
Recent studies have investigated the significance of GATA3 expression in patients with var-
ious malignant tumors. However, no previous studies have evaluated the clinicopathologi-
cal importance of GATA3 expression in soft tissue sarcomas (STS) patients.
Methods
We evaluated GATA3 expression in 76 STS cases using immunohistochemical analysis,
and statistically compared clinicopathological characteristics between GATA3-positive and
GATA3-negative cases.
Result
GATA3-positive expression was significantly associated with a higher mitotic count (P <
0.0001). Disease-free survival (DFS) of GATA3-positive cases was significantly shorter
than that of cases without GATA3 expression (P = 0.0104). Overall survival (OS) of GATA3-
positive cases was significantly shorter than that of cases without GATA3 expression (P =
0.0006). GATA3-positive expression was significantly associated with shorter DFS in both
univariate analysis (hazard ratio [HR], 2.719; P = 0.012) and multivariate analysis (HR,
2.711; P = 0.014). GATA3-positive expression was also significantly associated with worse
OS in both univariate analysis (HR, 5.730; P = 0.0007) and multivariate analysis (HR,
5.789; P = 0.0008).
Conclusion
These results indicate that GATA3 is an independent prognostic factor and suggest that
evaluation of GATA3 expression might enable more effective clinical follow-up using prog-
nostic stratification of STS patients.
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Introduction
Soft tissue sarcomas (STS), which involve mesenchymal cells, are malignant tumors that occur
throughout the body. It accounts for< 1% of all malignant tumors; nevertheless, it frequently
invades surrounding tissue and metastasizes to distant organs.[1,2] Surgical resection is recom-
mended for localized STS, although approximately half of patients experience recurrence even
though complete resection has been performed.[3] Moreover, one-third of patients eventually
die from their STS tumors.
STS tumors are graded according to the French Fédération Nationale des Centres de Lutte
Contre le Cancer (FNCLCC) system, in which grading is based on all sarcomas being consid-
ered as a single entity, because STS is rare and has many histological types.[4] However, this
grading system does not work well for all types of sarcomas.[5]
GATA3 is a transcription factor belonging to the GATA family, members of which bind to
the consensus DNA sequence G-A-T-A via zinc finger domains.[6] GATA3 expression is not
observed in normal mesenchymal tissue.[7] Previous studies have suggested the important role
of GATA3 in the proliferation and differentiation phases in a variety of normal tissue and
organs.[6] In T-cell development, GATA3 is well-known to be an essential transcription factor
in the differentiation of naive T cells to Th2 cells.[8] Additional GATA3 functions, including
maintaining differentiation, adhesion, and proliferation of epithelial cells in tissues such as the
mammary gland and skin, have also been reported,[9–12] as well as a role in the development
of sympathetic neurons.[13]
Recent studies have reported GATA3 expression in neoplastic cells in patients with various
malignant tumors, including breast cancer, gastric cancer, and neuroblastoma.[14–17] Some
studies reported that decreased GATA3 expression in neoplastic cells compared to non-neo-
plastic cells was associated with poorer overall survival (OS) in breast cancer and gastric cancer.
In contrast, studies in neuroblastoma indicated that increased GATA3 expression may be a
poor prognostic marker for OS.[18] On the other hand, GATA3 expression was reported to be
associated with expression of cyclinD1, HER2, and FOXO1, which might cause a worse clinical
outcome. [17,19–21]
Only a few reports of GATA3 expression in neoplastic cells have been published in patients
with mesenchymal tumors.[7] A patient with biphasic synovial sarcoma showed sporadic
GATA3 expression; in contrast, focal to extensive expression was observed in patients with
myxofibrosarcoma, undifferentiated/unclassified sarcomas, poorly differentiated angiosar-
coma, leiomyosarcoma, and malignant peripheral nerve sheath tumor. It is remarkable that no
previous studies have discussed the clinicopathological and prognostic importance of GATA3
expression in neoplastic cells of STS.
In this study, we investigated GATA3 expression using immunohistochemical (IHC) analy-
sis, and evaluated the statistical association between this expression and clinicopathological
features in STS cases.
Materials and Methods
Patients and samples
We reviewed formalin-fixed paraffin-embedded (FFPE) tissue samples from 76 STS patients
who underwent tumor resection at the Department of Orthopedic Surgery in Kurume Univer-
sity Hospital from July 1998 to August 2014. Most of the patients in this study were included in
the authors’ previous study.[22] In all cases, the pathological diagnoses were reviewed by 2
pathologists (OK and MH), according to the 2013 World Health Organization (WHO) classifi-
cation.[23] Clinical information was obtained from patient medical charts. The use of clinical
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information and materials was approved by the Research Ethics Committee of Kurume Uni-
versity and was in accordance with the Declaration of Helsinki. According to the committee,
informed consent was obtained.
In this study, all STS patients were provided with initial diagnoses, and underwent surgical
complete resection with confirmed microscopic negative surgical margins. Cases with disease
recurrence, synchronous metastasis, or who had received neoadjuvant therapies prior to surgi-
cal resection were excluded. All of the patients underwent periodical clinical follow-up at least
every other year after resection (range, 0–146 months).
Determination of GATA3 expression in soft tissue sarcomas
Each sarcoma sample was cut in maximum cross section. All of those samples were stained
with hematoxylin and eosin for morphological investigation. We evaluated the pathomorph-
ism of tumor cells by light microscope in slides made from those sections and selected the slide
including most characteristic pathological features for the present study.
A GATA3 primary antibody (1:50, rabbit monoclonal, D13C9, Cell Signaling Technology,
Danvers, MA) was used for IHC analysis. The detailed IHC protocol for GATA3 is as follows:
FFPE tissue samples were sectioned at a thickness of 2.5 μm, and deparaffinized in xylene fol-
lowed by 95% alcohol. After rehydration with H2O, antigen retrieval was performed with Tris-
ethylenediaminetetraacetic acid buffer (pH 9.0) in a microwave oven at 95°C for 40 minutes.
Endogenous peroxidase activity was blocked by incubation in 3% H2O2 solution for 5 minutes,
followed by incubation with the GATA3 primary antibody for 60 minutes at room tempera-
ture. Samples were then incubated with an EnVision Detection Systems (Dako) secondary anti-
body for 30 minutes. Visualization of GATA3 was performed using diaminobenzidine (DAB)
for 4 minutes.
The authors analyzed STS samples to define GATA3 positivity in each case based on the
propensity of GATA3-positive neoplastic cells within all neoplastic cells in a 5-mm2 area. A
neoplastic cell was defined as positive when the nucleus was stained at least weakly Authors
detected the intensity of those staining by using criteria of other malignancy.[24] In all cases,
the characterization of GATA3 positivity was evaluated using an optical microscope under
400-fold magnification in the field that showed the strongest immunoreaction of GATA3 in
tumor regions. Vascular endothelial cells were used as negative control and Th2 type T-cells
were done as positive control in immunohistochemistry of GATA3. Two independent observ-
ers (OK and MH) assessed GATA3 expression without any previous knowledge of clinical
information.
The GATA3 positivity cutoff value was determined to be 4%, which was the median value of
all STS cases in this study. Cases with a value> 4% were defined as GATA3-positive cases,
while those with a value 4% were defined as GATA3-negative cases.
Immunohistochemical detection of cyclin D1 and ErbB2 /HER2
expression
Primary antibodies used for immunohistochemistry were as follows: rabbit monoclonal anti-
Cyclin D1 (1:100, M3642, DAKO, Tokyo, Japan): mouse monoclonal anti-ErbB2/HER2 (1:400,
29D8, Cell Signaling Technology, Danvers, MA). They were used for IHC analysis. The cutoff
value of cyclin D1 and ErbB2/HER2 positivity was determined to be 10%.[25] Cases with the
value> 10% were defined as positive cases, while those with the value 10% were done as neg-
ative cases.
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Statistical methods
Clinicopathological characteristics for the statistical comparison included prognostic factors
identified in previous reports, including sex, age (< 60 or 60 years),[26] tumor size ( 5 cm
or> 5 cm),[26–28] tumor depth (superficial or deep),[26] and FNCLCC histological grade
(grade 1 or 2/3), tumor differentiation (score 1 or 2/3), mitotic count (0-9/10 or 10/10 high-
power fields [HPF]), and degree of tumor necrosis (< 50% or 50%).[4,28]
The statistical association between clinicopathological characteristics and GATA3 expres-
sion was analyzed by chi-square test or Fisher’s exact test (two-tailed test). Disease-free survival
(DFS) and OS were defined as the intervals between the day of pathological diagnosis and
recurrence or death, respectively. DFS and OS curves were calculated using the Kaplan-Meier
method, and a log-rank test was applied to evaluate statistical differences. Univariate and mul-
tivariate analyses were performed by a Cox proportional hazards model to assess the influence
of each variable on DFS and OS. A P-value< 0.05 was considered to indicate statistical signifi-
cance. Statistical analyses performed in this study were conducted using JMP software, version
11 (SAS institute, Tokyo, Japan).
Result
Clinicopathological characteristics
Histological types according to the WHO histological classification and clinicopathological fea-
tures of all cases included in this study are shown in Tables 1 and 2, respectively. This study
included 45 males (59.2%) and 31 females (40.8%) with a median age of 58.9 years (range,
8–88 years). The mean tumor size was 8.55 cm (range, 1–25 cm). With tumor orientation
demarcated by the muscular fascia, superficial tumors were observed in 25 cases (32.9%), while
deep tumors were observed in 51 cases (67.1%). FNCLCC histological grade was evaluated as
score 1 in 12 cases (15.8%), score 2 in 24 cases (31.6%), and score 3 in 40 cases (52.6%). Positive
expression of cyclin D1 and ErbB2/HER2 were seen in 44 cases (57.9%) and 0 case (0%) of sar-
comas, respectively. Regarding additional treatment after resection, no additional therapy was
performed in 49 cases (64.5%), radiotherapy was given in 14 cases (18.4%), chemotherapy was
given in 8 cases (10.5%), and chemoradiotherapy was given in 5 cases (6.6%). During the fol-
low-up period (mean, 51.1 months; range, 1–146 months), 16 cases (21.1%) died of local recur-
rence or distant metastasis.
Immunohistochemical detection of GATA3 expression in soft tissue
sarcoma
Representative tissue samples are shown in Fig 1. GATA3 expression was detected only within
nuclei of neoplastic cells in all cases. Fig 2 showed the distribution of the GATA3 positive rate.
The median GATA3 positivity value was 4% (range, 0–80%). Any tendencies between GATA3
expression and morphological and immunohistochemical findings was not observed. With
respect to histological type, GATA3-positive expression was observed in 47.3% (9/19) of undif-
ferentiated/unclassified sarcomas cases, 18.1% (2/11) of myxoid liposarcoma cases, 42.9% (3/7)
of well differentiated liposarcoma cases, 50.0% (1/2) of dedifferentiated liposarcoma cases,
80.0% (8/10) of leiomyosarcoma cases, 40.0% (4/10) of myxofibrosarcoma cases, 100.0% (3/3)
of synovial sarcoma cases, 75.0% (3/4) of malignant peripheral nerve sheath tumor cases,
66.7% (2/3) of extraskeletal osteosarcoma cases, 66.7% (2/3) of fibrosarcoma cases, 0.0% (0/2)
of alveolar soft part sarcoma cases, 100.0% (1/1) of epithelioid sarcoma cases, and 0.0% (0/1) of
rhabdomyosarcoma cases.
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Statistical association between GATA3 expression and
clinicopathological characteristics in soft tissue sarcoma
Table 3 shows the statistical association between clinicopathological characteristics and
GATA3 expression in this study. GATA3-positive expression significantly associated with a
higher number of mitotic counts (P< 0.0001). In contrast, no significant differences in sex
(P = 0.815), age (P = 0.247), tumor size (P = 0.791), depth (P = 0.807), FNCLCC histological
grade (P = 0.113), tumor differentiation (P = 1.000), degree of tumor necrosis (P = 0.615),
cyclinD1-positive (P = 0.1623), or ErbB2/HER2-positive (P-value, not calculable).
Table 1. Patient Characteristics.
Characteristic All (n = 76) (%)
Sex Male 45 (59.2%)
Female 31 (40.8%)
Age (years old) Mean [range] 58.9 [8–88]
 60 33 (43.4%)
> 60 43 (56.6%)
Primary tumor size (cm) Mean [range] 8.55 [1–25]
 5 19 (25.0%)
> 5 57 (75.0%)
Depth Superficial 25 (32.9%)
Deep 51 (67.1%)
FNCLCC histological grade 1 12 (15.8%)
2 24 (31.6%)
3 40 (53.6%)
Tumor differentiation 1 7 (9.2%)
2 26 (34.2%)
3 43 (56.6%)
Mitotic count 0-9/10HPF 29 (38.2%)
10-19/10HPF 15 (19.7%)
> 19/10HPF 32 (42.1%)
Tumor necrosis No necrosis 21 (27.6%)
< 50% 51 (67.1%)
 50% 4 (5.3%)
Cyclin D1 Negative 32(42.1%)
Positive 44(57.9%)
ErbB2/HER2 Negative 76(100%)
Positive 0(0%)
Initial treatment Surgery alone 49 (64.5%)
Surgery followed by radiotherapy 14 (18.4%)
Surgery followed by chemotherapy 8 (10.5%)
Surgery followed by chemoradiotherapy 5 (6.6%)
Follow up (months) Mean [range] 51.1 [1–146]
Prognosis Tumor death 16 (21.1%)
Non-tumor death 2 (2.6%)
Alive 58 (76.3%)
HPF, high-power fields; FNCLCC, French Fédération Nationale des Centres de Lutte Contre le Cancer.
doi:10.1371/journal.pone.0156524.t001
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Disease-free survival according to GATA3 expression in soft tissue
sarcoma
Fig 3 showed the DFS curves by GATA3 expression in STS cases. The DFS of GATA3-positive
cases was significantly shorter than that of GATA3-negative cases (P = 0.0104) (Fig 3A). In the
analysis stratified by FNCLCC histological grade, the DFS curves were not statistically different
between GATA3-positive and -negative cases among FNCLCC histological grade 1 cases
(P = 0.5637) (Fig 3B). However, in among FNCLCC histological grade 2 and 3 cases, GATA3--
positive cases experienced significantly shorter DFS compared to GATA3-negative cases
Table 2. Histological type of STS.
Histological type All (n = 76) (%)
Undifferentiated/unclassified sarcomas 19 (24.5%)
Myxoid liposarcoma 11 (14.5%)
Well differentiated liposarcoma 7 (9.2%)
Dedifferentiated liposarcoma 2 (2.6%)
Leiomyosarcoma 10 (13.2%)
Myxofibrosarcoma 10 (13.2%)
Synovial sarcoma 3 (3.9%)
Malignant peripheral nerve sheath tumor 4 (5.3%)
Extraskeletal osteosarcoma 3 (3.9%)
Fibrosarcoma 3 (3.9%)
Alveolar soft part sarcoma 2 (2.6%)
Epithelioid sarcoma 1 (1.3%)
Rhabdomyosarcoma 1 (1.3%)
STS, soft tissue sarcomas.
doi:10.1371/journal.pone.0156524.t002
Fig 1. Immunohistochemical detection of GATA3 expression in soft tissue sarcomas (Original magnification, x400; insert, x600).GATA3 was
present in the nuclei of STS cells at various proportions. (A) An undifferentiated/unclassified sarcomas case with 30%GATA3 expression. (B) A
leiomyosarcoma case with 80%GATA3 expression. (C) A malignant peripheral nerve sheath tumor case with 70%GATA3 expression. (D) A myxoid
liposarcoma case with 7%GATA3 expression.
doi:10.1371/journal.pone.0156524.g001
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(P = 0.0160) (Fig 3C). In the analysis stratified by tumor size, the DFS curves were not statisti-
cally different between GATA3-positive and -negative cases among cases with 5-cm tumors
(P = 0.1586) (Fig 3D). However, among cases with> 5-cm tumors, GATA3-positive cases
experienced significantly shorter DFS compared to GATA3-negative cases (P = 0.0256)
(Fig 3E).
Overall survival according to GATA3 expression in soft tissue sarcoma
OS curves by GATA3 expression are shown in Fig 4. OS for GATA3-positive cases was signifi-
cantly shorter than that for GATA3-negative cases (P = 0.0006) (Fig 4A). In the analysis strati-
fied by FNCLCC histological grade, GATA3-positive cases experienced significantly shorter
OS compared to GATA-negative cases among both FNCLCC histological grade 1 cases
(P = 0.0455) (Fig 4B) and grade 2/3 cases (P = 0.0047) (Fig 4C). When stratified by tumor size,
Fig 2. The distribution of GATA3 positive rate in soft tissue sarcomas. (A) The histogram of the GATA3
positive rate shows skewed distribution in all cases. (B) The histogram of GATA3 which focuses the
percentage from 0 to 10 with the longitudinal axis by every 1 percent.
doi:10.1371/journal.pone.0156524.g002
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the OS curves did not significantly differ between GATA3-positive and -negative cases among
cases with tumors 5 cm (P = 0.0779) (Fig 4D). However, among cases with tumors> 5 cm,
GATA3-positive cases experienced significantly shorter DFS compared to GATA3-negative
cases (P = 0.0040) (Fig 4E).
Univariate and multivariate analyses of disease-free survival and overall
survival in relation to GATA3 expression in soft tissue sarcoma
The results of univariate and multivariate analyses for DFS and OS with respect to GATA3
expression are presented in Tables 4 and 5. Based on the DFS analysis, GATA3-positive expres-
sion was significantly associated with worse DFS in univariate analysis (hazard ratio [HR],
2.719; P = 0.012). GATA3-positive expression was also identified as an independent risk factor
for recurrence in multivariate analysis (HR, 2.711; P = 0.014). For OS, GATA3-positive expres-
sion was significantly associated with worse OS in univariate analysis (HR, 5.730; P = 0.0007),
and GATA3-positive expression was also identified as an independent poor prognostic factor
for OS in multivariate analysis (HR, 5.789; P = 0.0008).
Discussion
The results of this study show for the first time that GATA3-positive STS has significantly
more mitotic counts compared to GATA3-negative STS. DFS and OS of GATA3-positive cases
were significantly shorter than those of GATA-negative cases. Stratified analyses also indicated
that GATA3-positive STS was associated with significantly shorter DFS and OS among cases
with larger tumors and higher FNCLCC histological grades. Moreover, GATA3-positive
Table 3. Statistical association between clinical characteristics and GATA3 expression.
Characteristic GATA3 positive n = 38 (50.0%) GATA3 negative n = 38 (50.0%) P-value (Chi-square)
Sex Male 22 23 0.815
Female 16 15
Age (years old)  60 14 19 0.247
> 60 24 19
Primary tumor size (cm)  5 9 10 0.791
> 5 29 28
Depth Superficial 13 12 0.807
Deep 25 26
FNCLCC histological grade 1 3 9 0.113※
2&3 35 29
Tumor differentiation 1 3 4 1.000※
2&3 35 34
Mitotic count 0-9/10HPF 6 23 <0.0001
 10/10HPF 32 15
Tumor necrosis < 50% 37 35 0.615※
 50% 1 3
cyclin D1 Negative 19 25 0.1623
Positive 19 13
ErbB2 /HER2 Negative 38 38
Positive 0 0
※p-value derived from Fisher's exact test.
doi:10.1371/journal.pone.0156524.t003
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Fig 3. Comparison of disease-free survival curves between GATA3-positive (continuous line) and -negative (dotted line) STS cases. (A)
Among all STS cases, GATA3-positive cases experienced significantly worse DFS compared to GATA3-negative cases (P = 0.0104). (B) Among
GATA3 in Soft Tissue Sarcomas
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expression was shown to be both an independent risk factor for recurrence and a poor prog-
nostic factor for OS in multivariate analysis. The HR of GATA3-positive expression was high-
est among reported prognostic factors.[4,26–29] It cannot be denied that the relatively small
number of cases in this study may have influenced these results. Nevertheless, GATA3 expres-
sion appears to be a better prognostic factor than previously identified factors.
As mentioned above, GATA3-positive cases experienced significantly shorter DFS com-
pared to GATA3-negative cases. In multivariate analysis, GATA3-positive expression was also
detected as an independent risk factor influencing recurrence, in addition to tumor size. Several
studies have reported that tumor size[26,30,31] and FNCLCC histological grade[30] are inde-
pendent predictors for distant metastasis in STS. In addition, Stojadinovic et al. reported that
tumor size was also a significant risk factor for local recurrence.[32] The present results suggest
that GATA3 expression may be valuable in the stratification of patients for predicting recur-
rence, including both local recurrence and distant metastasis after complete resection, particu-
larly among cases with large tumors and/or a high FNCLCC histological grade.
Previous reports in other malignancies showed GATA3 expression was associated with acti-
vation of cyclin D1 and expression of ErbB2 /HER2, which might be leading to a poor progno-
sis. [17,20,21,33] However, there were no significant associations between GATA3 expression,
and cyclinD1 or ErbB2/HER2. Although underlying mechanisms are not clear in STS, these
results could emphasize the importance of GATA3 expression as a poor prognostic factor,
because GATA 3 expression was independent from cyclinD1 and HER2.
Even recently, there is no general consensus about the evaluation method of the positivity
cutoff value especially in GATA3. A definition of biologic cutoff value was also considered to
be difficult. In the previous studies of breast cancer which set cutoff value according to IHC
positivity, there is no consistency in determining GATA3 positivity among the studies. Each
studies set cutoff value of GATA3 positivity to 20% [34], 10% [35] and 5% [36]. The reason
why the cutoff value was adopted was not well declared in those manuscripts. In gastric adeno-
carcinoma, Keshari et al. defined that GATA3 immunostaining score was calculated as the sum
of the percentage of positively stained tumor cells and the staining intensity. The score ranged
from 0 to 9 and the cutoff value was set to be score 3.[14] There are several articles that define
the median as cutoff value, although they were not about GATA3 expression.[37–39] Indeed,
the histogram of GATA3 positivity in STS demonstrated skewed distribution as below (Fig
2A). Therefore, cutoff value in this study, which is the statistical median value, is considered to
be appropriate.
This study has some limitations. First, the relatively small number of patients made it diffi-
cult to evaluate the association between GATA3 expression and clinicopathological features of
each histological type. Additional studies including larger numbers of patients with each histo-
logical type are required; however, it should be noted that the majority of previous studies
grouped STS patients using the FNCLCC histological grading system.[23] Second, GATA3
expression was investigated only by IHC analysis. Additional analyses of genomic abnormali-
ties and/or transcriptional mechanisms are required to fully understand how GATA3 is
expressed biologically.
In this study, GATA3 expression was shown to be an independent risk factor for recurrence
after complete resection, as well as a prognostic factor for OS in STS patients. These results
FNCLCC histological grade 1 cases, no significant differences were observed between GATA-3 positive and -negative cases. (C) Among FNCLCC
histological grade 2/3 cases, GATA3-positive cases experienced significantly worse DFS compared to GATA3-negative cases (P = 0.0160). (D) Among
cases with tumors 5 cm, no significant differences were observed between GATA-3 positive and -negative cases. (E) Among cases with tumors > 5
cm, GATA3-positive cases experienced significantly worse DFS compared to GATA3-negative cases (P = 0.0256).
doi:10.1371/journal.pone.0156524.g003
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Fig 4. Comparison of overall survival curves between GATA3-positive (continuous line) and -negative (dotted line) cases. (A) Among all STS
cases, OS for GATA3-positive cases was significantly worse than that for GATA3-negative cases (P = 0.0006). (B) Among FNCLCC histological grade
GATA3 in Soft Tissue Sarcomas
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suggest that evaluation of GATA3 expression might contribute to more effective clinical strate-
gies. Further studies are required to clarify the functions and mechanisms of GATA3 in STS.
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Table 4. Univariate andmultivariate Cox regression analysis for disease-free survival in STS patients.
Characteristics Univariate analysis Multivariate analysis
Hazard ratio 95% confidence interval P value Hazard ratio 95% confidence interval P value
Age (years old) ( 60 vs  60) 1.359 0.639–3.014 0.429 1.315 0.581–3.069 0.513
Depth (superficial vs deep) 0.875 0.407–1.986 0.740 0.906 0.400–2.141 0.817
Primary tumor size (cm) ( 5 vs > 5) 2.631 1.013–8.973 0.047 2.885 1.095–9.928 0.031
FNCLCC histological grade (1 vs 2&3) 5.195 1.101–92.795 0.035 4.047 0.852–72.432 0.087
GATA3 (positive vs negative) 2.719 1.249–6.270 0.012 2.711 1.219–6.384 0.014
STS, soft tissue sarcomas; FNCLCC,French Fédération Nationale des Centres de Lutte Contre le Cancer.
doi:10.1371/journal.pone.0156524.t004
Table 5. Univariate andmultivariate Cox regression analysis for overall survival in STS patients.
Characteristics Univariate analysis Multivariate analysis
Hazard ratio 95% confidence interval P value Hazard ratio 95% confidence interval P value
Age (years old) ( 60 vs  60) 1.521 0.597–4.152 0.382 1.556 0.594–4.344 0.370
Depth(superficial vs deep) 0.879 0.340–2.530 0.798 1.059 0.399–3.121 0.912
Primary tumor size (cm) ( 5 vs > 5) 3.176 0.894–20.168 0.077 3.416 0.952–21.813 0.061
FNCLCC histological grade (1 vs 2&3) 2.650 0.533–48.004 0.277 1.373 0.264–25.197 0.752
GATA3 (positive vs negative) 5.730 2.024–20.418 0.0007 5.789 2.012–20.880 0.0008
STS, soft tissue sarcomas; FNCLCC,French Fédération Nationale des Centres de Lutte Contre le Cancer.
doi:10.1371/journal.pone.0156524.t005
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